The FDA approved the first blood test to aid in diagnosing Alzheimer's disease. The Lumipulse G test measures proteins in blood plasma to detect amyloid plaques, a hallmark of the disease. This less invasive method offers an alternative to costly and time-consuming PET scans or spinal taps. While highly accurate (91.7% positive results correctly identified plaques, 97.3% negative results confirmed absence), it's not a standalone diagnostic and requires interpretation with other clinical information. The test is intended for patients with cognitive impairment, aged 55 and older, showing Alzheimer's symptoms. This breakthrough device aims to improve early detection and treatment access for the millions of Americans affected by Alzheimer's.

Prepared by Olivia Bennett and reviewed by editorial team.